Yonaha M, Tampo Y, Clarke W, Davis H W, Schenkman J B
Department of Pharmacology, University of Connecticut Health Center, Farmington 06030.
Arch Biochem Biophys. 1992 Jan;292(1):62-9. doi: 10.1016/0003-9861(92)90051-w.
NADPH-supported lipid peroxidation monitored by malondialdehyde (MDA) production in the presence of ferric pyrophosphate in liver microsomes was inactivated by heat treatment or by trypsin and the activity was not restored by the addition of purified NADPH-cytochrome P450 reductase (FPT). The activity was differentially solubilized by sodium cholate from microsomes, and the fraction solubilized between 0.4 and 1.2% sodium cholate was applied to a Sephadex G-150 column and subfractionated into three pools, A, B, and C. MDA production was reconstituted by the addition of microsomal lipids and FPT to specific fractions from the column, in the presence of ferric pyrophosphate and NADPH. Pool B, after removal of endogenous FPT, was highly active in catalyzing MDA production and the disappearance of arachidonate and docosahexaenoate, and this activity was abolished by heat treatment and trypsin digestion, but not by carbon monoxide. The rate of NADPH-supported lipid peroxidation in the reconstituted system containing fractions pooled from Sephadex G-150 columns was not related to the content of cytochrome P450. p-Bromophenylacylbromide, a phospholipase A2 inhibitor, inhibited NADPH-supported lipid peroxidation in both liver microsomes and the reconstituted system, but did not block the peroxidation of microsomal lipid promoted by iron-ascorbate or ABAP systems. Another phospholipase A2 inhibitor, mepacrine, poorly inhibited both microsomal and pool-B'-promoted lipid peroxidation, but did block both iron-ascorbate-driven and ABAP-promoted lipid peroxidation. The phospholipase A2 inhibitor chlorpromazine, which can serve as a free radical quencher, blocked lipid peroxidation in all systems. The data presented are consistent with the existence of a heat-labile protein-containing factor in liver microsomes which promotes lipid peroxidation and is not FPT, cytochrome P450, or phospholipase A2.
在肝微粒体中,通过丙二醛(MDA)生成来监测的由焦磷酸铁存在下的NADPH支持的脂质过氧化反应,经热处理或胰蛋白酶处理后失活,并且添加纯化的NADPH - 细胞色素P450还原酶(FPT)后活性未恢复。该活性可被胆酸钠从微粒体中差异溶解,将在0.4%至1.2%胆酸钠之间溶解的部分应用于Sephadex G - 150柱,并再细分为三个组分,A、B和C。在焦磷酸铁和NADPH存在下,通过向柱中的特定组分添加微粒体脂质和FPT来重建MDA生成。去除内源性FPT后的组分B在催化MDA生成以及花生四烯酸和二十二碳六烯酸消失方面具有高活性,并且该活性经热处理和胰蛋白酶消化后被消除,但一氧化碳处理后未被消除。含有从Sephadex G - 150柱汇集的组分的重建系统中,NADPH支持的脂质过氧化速率与细胞色素P450的含量无关。磷脂酶A2抑制剂对溴苯甲酰溴抑制肝微粒体和重建系统中NADPH支持的脂质过氧化反应,但不阻断铁 - 抗坏血酸或ABAP系统促进的微粒体脂质过氧化。另一种磷脂酶A2抑制剂米帕林对微粒体和组分B'促进的脂质过氧化反应抑制作用较弱,但确实阻断了铁 - 抗坏血酸驱动的和ABAP促进的脂质过氧化反应。可作为自由基淬灭剂的磷脂酶A2抑制剂氯丙嗪阻断了所有系统中的脂质过氧化反应。所呈现的数据与肝微粒体中存在一种促进脂质过氧化的热不稳定含蛋白质因子一致,该因子不是FPT、细胞色素P450或磷脂酶A2。